multivari analysi prognost factor stage IV follicular low-grad lymphoma risk model record untreat patient stage IV follicular low-grad lymphoma flgl cyclophosphamid doxorubicin vincristin prednison bleomycin chop-bleo chemotherapi overal complet remiss CR rate median follow-up month cause-specif surviv rate median surviv month failure-fre surviv ff year median ff month multivari analysi peripher lymph node size LN degre marrow involv sex order import ff number extranod site en LN sex degre marrow involv import cause-specif surviv tumor burden TB model en LN degre marrow involv group signific differ cause-specif surviv ff low TB en exclus extens marrow nodal diseas cm cause-specif surviv patient high TB equal en nodal diseas equal cm intermedi TB equal en extens marrow nodal diseas cm patient low TB ff rate intermedi high TB group ff sex strong prognost variabl risk model surviv ff TB sex femal low TB prognosi surviv ff year male high TB outlook median surviv ff month other tb-sex combin group signific differ surviv compar ff model design analysi futur trial 